Acute Leukemias: Mastering the Latest Developments in the Absence of Targetable Mutations

Gain insights into the latest advances in the use of new approaches for treating patients with ALL and AML including biomarkers new targeted agents safety considerations and clinical trials through expert-guided discussion and case-based examples.

Share

Program Content

Activities

<i>EP:</i> Tx in Acute Leukemias
ExpressPoints Acute Leukemias: Mastering the Latest Developments in the Absence of Targetable Mutations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 14, 2020

Expires: July 13, 2021

New Tx strategies in ALL
Expert Guidance on Optimizing Treatment Strategies for Acute Lymphoblastic Leukemia
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 10, 2020

Expires: July 09, 2021

New Tx strategies in AML
Acute Myeloid Leukemia: Mastering the Latest Developments in the Absence of Targetable Mutations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 10, 2020

Expires: July 09, 2021

Activities

Acute Leukemias: Latest Developments
Acute Leukemias: Mastering the Latest Developments in the Absence of Targetable Mutations
Congratulations: You achieved a completion on 04/09/2022

Activities

R/R ALL
How I Use Blinatumomab and Inotuzumab Ozogamicin in Patients With Relapsed/Refractory ALL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 30, 2020

Expires: September 29, 2021

Activities

Acute Leukemias: FAQ
Developments in Acute Leukemias: Expert Answers to Clinician Questions
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: October 02, 2020

Expires: October 01, 2021

Faculty

cover img faculity

David Marks, MD, PhD

Professor of Haematology and Stem Cell Transplanation
Department of Haematology and BMT
University of Bristol
University Hospitals Bristol NHS
Bristol, United Kingdom

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.